Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 51

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 51
---
 they be entitled to participate in any meeting of the holders of Common Stock, except as provided in
the Certificate of Designations (or as otherwise required by applicable law).

Covenants. The Series D
Certificate of Designations contains a variety of obligations on the Company’s part not to engage in specified activities. In particular,
the Company will not, and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or distribution
on any of the Company’s capital stock (other than as required under the Series D Certificate of Designations) and will not
incur any indebtedness other than ordinary course trade payables or, subject to certain exceptions, incur any liens. In addition, the
Company will not issue any preferred stock or issue any other securities that would cause a breach or default under the Series D
Certificate of Designations.

Reservation Requirements.
So long as any Series D Preferred Stock remains outstanding, the Company shall at all times reserve at least 250% of the number of
shares of Common Stock as shall from time to time be necessary to effect the conversion of all Series D Preferred Stock then outstanding.

On April 21, 2025, the Company
entered into a Securities Purchase Agreement (the “Fourth Securities Purchase Agreement”) with certain accredited investors.
Pursuant to the Fourth Securities Purchase Agreement, up to 10,000 shares of the Company’s Series D Preferred Stock shall be purchased
for an aggregate purchase price of up to $8 million in one or more closings.

<div align='center'>20</div>

On April 22, 2025, pursuant
to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth
PIPE Financing”), 6,250 shares of the Series D Preferred Stock in exchange for the receipt of 1,000,279 shares of Series D Preferred
Stock of Stella Diagnostics, Inc, (the “Stella Series D Preferred Stock”), in lieu of cash, which is included in investment
in equity securities on the accompanying unaudited condensed balance sheet as of September 30, 2025. Pursuant to the Fourth PIPE Financing,
on April 22, 2025, the Company issued 6,250 shares of its Series D Preferred Stock to investors in exchange for 1,000,279 shares of Series
D Preferred Stock of Stella Diagnostics, in which a portion of the Series D Preferred Stock of Stella Diagnostics was owned by a